

Press release
May 11, 2005
Gothenburg, Sweden

Annual General Meeting in Vitrolife AB (publ)

At Vitrolife's Annual General Meeting yesterday, May 10, the following was among the decided:

- No dividend will be paid for the financial year 2004.
- Re-election of Board members Patrik Tigerschiöld, Per Båtelson, Lars Hamberger and Madeleine Olsson-Eriksson, in accordance with the nominations committee's proposal.
- Decision regarding the adoption of a resolution regarding instructions concerning principles for the appointment of the company's election committee. The instructions also contain rules for the election committee's tasks, meetings and changes to the instructions.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,800,000 shares in total, corresponding to approximately 9.8 percent of the company's share capital. The issue may deviate from the shareholders' pre-emptive rights through a non-cash issue. The reason for the possible deviation from the shareholders' pre-emptive rights is to prepare the ground for a possible company acquisition.

At the Board meeting following election which was held after the Annual General Meeting, Patrik Tigerschiöld was elected Chairman of the Board.

May 11, 2005
Gothenburg, Sweden

The Board

Questions should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.

Vitrolife today has approximately 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungälv, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungälv, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.